A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 17, Issue 1, 2007, Pages 13-23

  Hanefeld, Markolf ^a   Patwardhan, Rita ^b   Jones, Nigel P ^c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Comparative study; Efficacy; Glibenclamide; Rosiglitazone; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; FATTY ACID; GLIBENCLAMIDE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FATTY ACIDS, NONESTERIFIED; FEMALE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 33845339600     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2005.12.003     Document Type: Article

References (39)

1. DeFronzo R.A. Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. Diabetologia 35 (1992) 389-397
2. Polonsky K.S., Sturis J., and Bell G.I. Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 334 (1996) 777-783
3. Matthews D.R., Cull C.A., Stratton I.M., Holman R.R., and Turner R.C. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 15 (1998) 297-303
4. Saltiel A.R., and Olefsky J.M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45 (1996) 1661-1669
5. Miyazaki Y., Glass L., Triplitt C., Matsuda M., Cusi K., Mahankali A., et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 44 (2001) 2210-2219
6. Carey D.G., Cowin G.J., Galloway G.J., Jones N.P., Richards J.C., Biswas N., et al. Sensitivity effect of rosiglitazone on insulin and body composition in type 2 diabetic patients. Obes Res 10 (2002) 1008-1015
7. Lebovitz H.E., Dole J.F., Patwardhan R., Rappaport E.B., and Freed M.I. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86 (2001) 280-288
8. Phillips L.S., Grunberger G., Miller E., Patwardhan R., Rappaport E.B., and Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Rosiglitazone Clinical Trials Study Group. Diabetes Care 24 (2001) 308-315
9. Raskin P., Rappaport E.B., Cole S.T., Yan Y., Patwardhan R., and Freed M.I. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 43 (2000) 278-284
10. Patel J., Anderson R.J., and Rappaport E.B. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1 (1999) 165-172
11. St John Sutton M., Rendell M., Dandona P., Dole J.F., Murphy K., Patwardhan R., et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes mellitus. Diabetes Care 25 (2002) 2058-2064
12. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 16 (1999) 179-192
13. Holstein A., and Egberts E.H. Risk of hypoglycaemia with oral antidiabetic agents in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 111 (2003) 405-414
14. Virtanen K.A., Hällsten K., Parkkola R., Janatuinen T., Lonnqvist F., Viljanen T., et al. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 52 (2003) 283-290
15. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108 (2003) 2941-2948
16. Lebovitz H.E. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 18 Suppl. 2 (2002) S23-S29
17. Allauzen S., Joly S., Granier C., Molina F., Bouix O., Pau B., et al. Immunoanalysis of human insulin using monoclonal antibodies reveals antigenicity of evolutionarily conserved residues. Mol Immunol 32 (1995) 27-36
18. Allauzen S., Mani J.C., Granier C., Pau B., and Bouanani M. Epitope mapping and binding analysis of insulin-specific monoclonal antibodies using a biosensor approach. J Immunol Methods 183 (1995) 27-32
19. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
20. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
21. Viberti G., Kahn S.E., Greene D.A., Herman W.H., Zinman B., Holman R.R.A., et al. Diabetes Outcome Progression Trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 25 (2002) 1737-1743
22. Finegood D.T., McArthur M.D., Kojwang D., Thomas D., Topp B., Leonard T., et al. Beta-cell mass dynamics in zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 50 (2001) 1021-1029
23. Smith S.A., Lister C.A., Toseland C.D., and Buckingham R.E. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. Diabetes Obes Metab 2 (2000) 363-372
24. Buckingham R.E., Al-Barazanji K.A., Toseland C.D., Slaughter M., Connor S.C., West A., et al. Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 47 (1998) 1326-1334
25. Nolan J.J., Jones N.P., Patwardhan R., and Deacon L.F. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med 17 (2000) 287-294
26. Davies M.J., Metcalfe J., Day J.L., Grenfell A., Hales C.N., and Gray I.P. Effect of sulphonylurea therapy on plasma insulin, intact and 32/33 split proinsulin in subjects with type 2 diabetes mellitus. Diabet Med 11 (1994) 293-298
27. Smith S.A., Porter L.E., Biswas N., and Freed M.I. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes. J Clin Endocrinol Metab 89 (2004) 6048-6053
28. Roder M.E., Porte Jr. D., Schwartz R.S., and Kahn S.E. Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 83 (1998) 604-608
29. Randle P.J., Garland P.B., Hales C.N., and Newsholme E.A. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1 (1963) 785-789
30. Mayerson A.B., Hundal R.S., Dufour S., Lebon V., Befroy D., Cline G.W., et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51 (2002) 797-802
31. Freed M.I., Ratner R., Marcovina S.M., Kreider M.M., Biswas N., Cohen B.R., et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 90 (2002) 947-952
32. Brunzell J.D., Marcovina S., Yu D., Cobitz A., Gould E., Chen H., et al. Rosiglitazone reduces novel biomarkers of cardiovascular disease in subjects with type 2 diabetes mellitus already on statin therapy. J Am Coll Cardiol 43 Suppl. (2004) 504A
33. Sobel B.E., Frye R., and Detre K.M. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation 107 (2003) 636-642
34. Home P., and Gubb J. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): a long-term cardiovascular outcome study. Diabetes 51 Suppl. 2 (2002) A487
35. Kannel W.B., and Larson M. Long-term epidemiologic prediction of coronary disease. The Framingham experience. Cardiology 82 (1993) 137-152
36. Bennett S.M., Agrawal A., Elasha H., Heise M., Jones N.P., Walker M., et al. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med 21 (2004) 415-422
37. Honisett S.Y., Stojanovska L., Sudhir K., Kingwell B.A., Dawood T., and Komesaroff P.A. Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes. Diabetes Care 26 (2003) 3194-3195
38. Home P., Komajada M., Beck-Nielsen H., Curtis P., Zambanini A., and Dargie H. Twelve months sustained efficacy of rosiglitazone combination therapy on ambulatory blood pressure (ABP) in people with type 2 diabetes mellitus. Diabetes 54 Suppl. 1 (2005) A134
39. King A.B. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 23 (2000) 557